Lonafarnib
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Lonafarnib: From Progeria to Leprosy
One-Sentence Summary
Lonafarnib is a farnesyltransferase inhibitor originally developed for Hutchinson-Gilford Progeria Syndrome (HGPS, a rare premature aging disorder), with investigational use also explored in hepatitis B/D infection. The TxGNN model predicts a possible link to Leprosy, but this prediction is currently supported by 0 clinical trials and 0 publications, and lacks any identifiable mechanistic rationale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hutchinson-Gilford Progeria Syndrome (early aging syndrome) — noted from repurposing rationale text; no formal Taiwan regulatory record exists |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 99.14% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, verified mechanism-of-action data for lonafarnib is not available in this evidence pack (original MOA field is a data gap). However, contextual information indicates lonafarnib acts as a farnesyltransferase inhibitor, blocking farnesylation of Ras and other host-cell proteins — a pathway relevant to its approved use in HGPS and its investigational use in hepatitis delta virus infection (which relies on host farnesylation for viral assembly).
Leprosy, by contrast, is a bacterial infection caused by Mycobacterium leprae. This pathogen does not rely on the eukaryotic host farnesyltransferase substrate system that lonafarnib targets, and there is no established biological pathway connecting protein farnesylation inhibition to anti-leprosy activity. The prediction score of 99.14% appears to reflect a knowledge-graph link inferred by the TxGNN model rather than a mechanistically grounded hypothesis, and it is not corroborated by any preclinical, clinical, or literature evidence at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Lonafarnib is not currently marketed in Taiwan, and no product license records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (Evidence Level L5) with no clinical trials, no literature, and no plausible mechanistic link between farnesyltransferase inhibition and M. leprae infection. There is insufficient basis to advance this candidate at this time.
To proceed, the following is needed:
- Verified mechanism-of-action data for lonafarnib (DrugBank/primary literature)
- Preclinical or in vitro studies evaluating farnesylation-pathway relevance to M. leprae biology
- TFDA/regulatory labeling data (warnings, contraindications, DDI) to enable a baseline safety assessment
- Any emerging clinical or case-report evidence before reconsidering this indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.